Array BioPharma Inc. (ARRY)

14.85
0.01 0.07
NASDAQ : Health Technology
Prev Close 14.86
Open 14.49
Day Low/High 14.24 / 15.08
52 Wk Low/High 9.98 / 20.21
Volume 2.16M
Avg Volume 2.29M
Exchange NASDAQ
Shares Outstanding 212.92M
Market Cap 3.23B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

European Commission Approves BRAFTOVI® (encorafenib) In Combination With MEKTOVI® (binimetinib) For Advanced BRAF-mutant Melanoma

European Commission Approves BRAFTOVI® (encorafenib) In Combination With MEKTOVI® (binimetinib) For Advanced BRAF-mutant Melanoma

- European Commission approval applies to all 28 European Union member states, Liechtenstein, Iceland and Norway -

Array BioPharma Announces Publication Of BRAFTOVI® (encorafenib) MEKTOVI® (binimetinib) Phase 3 Overall Survival Data In The Lancet Oncology

Array BioPharma Announces Publication Of BRAFTOVI® (encorafenib) MEKTOVI® (binimetinib) Phase 3 Overall Survival Data In The Lancet Oncology

- BRAFTOVI + MEKTOVI demonstrated a median overall survival of 33.6 months in patients with advanced BRAF-mutant melanoma in Phase 3 COLUMBUS trial -

Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2018

Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2018

-- FDA approved BRAFTOVI™ (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced BRAF-mutant melanoma --

Array BioPharma Names Carrie S. Cox Chairman Of Its Board Of Directors

Array BioPharma Names Carrie S. Cox Chairman Of Its Board Of Directors

- Industry veteran brings strong commercial experience as Array commercializes BRAFTOVI™ + MEKTOVI® -

BRAFTOVI™ (encorafenib) MEKTOVI® (binimetinib) Receives Positive CHMP Opinion For Advanced BRAF-mutant Melanoma

BRAFTOVI™ (encorafenib) MEKTOVI® (binimetinib) Receives Positive CHMP Opinion For Advanced BRAF-mutant Melanoma

- Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival -

First Week Of ARRY March 2019 Options Trading

First Week Of ARRY March 2019 Options Trading

Investors in Array BioPharma Inc. saw new options begin trading this week, for the March 2019 expiration.

Array BioPharma Announces FDA Approval Of BRAFTOVI™ (encorafenib) In Combination With MEKTOVI® (binimetinib)

Array BioPharma Announces FDA Approval Of BRAFTOVI™ (encorafenib) In Combination With MEKTOVI® (binimetinib)

- Approval based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival -

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

Array BioPharma Announces Additional Median Overall Survival Results Of Encorafenib And Binimetinib In Patients With BRAF-mutant Advanced Melanoma

Array BioPharma Announces Additional Median Overall Survival Results Of Encorafenib And Binimetinib In Patients With BRAF-mutant Advanced Melanoma

-- Combination of encorafenib and binimetinib achieved 33.6 month median overall survival --

Interesting ARRY Put And Call Options For December 21st

Investors in Array BioPharma Inc. saw new options begin trading this week, for the December 21st expiration.

February Trade Ideas Rundown: How'd We Do?

February Trade Ideas Rundown: How'd We Do?

A fresh look at all 17 ideas: the winners, the losers and the still to be determined.

An Aggressive Trade in Array Biopharma

An Aggressive Trade in Array Biopharma

Despite biotech losing a bit of its former headline grabbing attention, there are still plenty of great setups to be found.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Array Biopharma Inc. Of Class Action Lawsuit And Upcoming Deadline - ARRY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Array Biopharma Inc. Of Class Action Lawsuit And Upcoming Deadline - ARRY

Pomerantz LLP announces that a class action lawsuit has been filed against Array Biopharma Inc.

Short Interest Drops 23.4% For ARRY

Short Interest Drops 23.4% For ARRY

The most recent short interest data has been released for the 12/15/2017 settlement date, which shows a 4,831,803 share decrease in total short interest for Array BioPharma Inc. , to 15,831,594, a decrease of 23.38% since 11/30/2017.

The Klein Law Firm Reminds Shareholders Of A Class Action On Behalf Of Array Biopharma Inc. Shareholders And A Lead Plaintiff Deadline Of January 22, 2018

The Klein Law Firm Reminds Shareholders Of A Class Action On Behalf Of Array Biopharma Inc. Shareholders And A Lead Plaintiff Deadline Of January 22, 2018

The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc.

ARRY EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Array Biopharma Inc. And A Lead Plaintiff Deadline Of January 22, 2018

ARRY EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Array Biopharma Inc. And A Lead Plaintiff Deadline Of January 22, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Array Biopharma Inc.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of...

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint On Behalf Of Array Biopharma Inc. Shareholders And Lead Plaintiff Deadline Of January 22, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed A Complaint On Behalf Of Array Biopharma Inc. Shareholders And Lead Plaintiff Deadline Of January 22, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Array Biopharma Inc.

The Klein Law Firm Notifies Shareholders Of A Class Action Commenced On Behalf Of Array Biopharma Inc. Shareholders And A Lead Plaintiff Deadline Of January 22, 2018

The Klein Law Firm Notifies Shareholders Of A Class Action Commenced On Behalf Of Array Biopharma Inc. Shareholders And A Lead Plaintiff Deadline Of January 22, 2018

The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc.

ARRY LOSS NOTICE: Rosen Law Firm Reminds Array Biopharma Inc. Investors Of Important Deadline In Class Action

ARRY LOSS NOTICE: Rosen Law Firm Reminds Array Biopharma Inc. Investors Of Important Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Array Biopharma Inc.

This Isn't a Rally: Cramer's 'Mad Money' Recap (Monday 12/4/17)

This Isn't a Rally: Cramer's 'Mad Money' Recap (Monday 12/4/17)

Investors continued to rotate into domestic stocks seen benefiting from tax cuts, but without higher estimates, the gains could falter.

ARRY INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Commencement Of A Class Action Involving Array Biopharma Inc. And A Lead Plaintiff Deadline Of January 22, 2018

ARRY INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Commencement Of A Class Action Involving Array Biopharma Inc. And A Lead Plaintiff Deadline Of January 22, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of investors who purchased Array Biopharma Inc.

TheStreet Quant Rating: D (Sell)